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Objective: Epicardial fat is considered as indicator of cardiovascular risk. Several studies have
tested the association between epicardial fat thickness (EFT) and coronary artery disease.
The aim of our study is to test the hypothesis that echocardiographic EFT is a marker of
coronary artery disease.
Methods: One hundred and ten patients (70 males and 40 females with mean age of 51.5
 10.6 and 52.6  9.6, respectively) admitted for coronary angiogram underwent assessment
of epicardial fat thickness by echocardiography. Routine clinical examination, evaluation of
risk factor proﬁle, and anthropometric variables were also done. Epicardial fat thickness was
measured on the free wall of right ventricle in parasternal long- and short-axis views at end-
systole for 3 cardiac cycles.
Results: Mean epicardial fat thickness in angiographically normal patients and acute coro-
nary syndromes were 4.4  1.2 and 6.9  1.9, respectively. Epicardial fat thickness in males
and females were not statistically different. Burden of coronary arterial lesions denoted by
Gensini score shows linear association with epicardial fat thickness and the severity of the
coronary disease.
Conclusion: Epicardial fat is independently and linearly associated with CAD and its severity.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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The heart and vessels are surrounded by layers of adipose
tissue, which is a complex organ composed of adipocytes,
stromal cells, macrophages, and a neuronal network, all
nourished by a rich microcirculation. The layers of adipose
tissue surrounding the heart can be subdivided into intra-
and extrapericardial fat. Their thicknesses and volumes can* Corresponding author.
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0019-4832/# 2015 Cardiological Society of India. Published by Elseviebe quantiﬁed by echocardiography and computed tomogra-
phy or magnetic resonance imaging, respectively.1,2 The
term extrapericardial fat deﬁnes thoracic adipose tissue
external to the parietal pericardium. It originates from
primitive thoracic mesenchymal cells and thus derives its
blood supply from noncoronary sources.3 Intrapericardial fat
is further subdivided into epicardial and pericardial fat.
Anatomically, epicardial and pericardial adipose tissues are
clearly different.3,4 Epicardial fat is located between the outerr B.V. All rights reserved.
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um.
Pericardial fat is anterior to the epicardial fat and therefore
located between visceral and parietal pericardium. Much of
the importance within the epicardial fat is its anatomical
closeness to the myocardium and the fact that the two tissues
share the same microcirculation.
The epicardial fat layer originates from mesothelial cells
and hence obtains its vascular supply from the coronary
arteries. It has been shown that epicardial fat is metabolically
active and a source of several adipokines and inﬂammatory
cytokines, and there seems to be potential interactions
through paracrine or vasocrine mechanisms between epicar-
dial fat and myocardium.5–8 This is clearly not true for the
pericardial fat. Gensini scoring system is a good tool to
quantify coronary stenosis.9 Some studies correlated epicar-
dial fat thickness with severity of coronary stenosis with
conﬂicting results. Therefore, the aim of our study is to
evaluate the hypothesis that there is a correlation between
echocardiographic EFT thickness and severity of coronary
artery disease.
2. Methods
2.1. Study design
The study was designed as an observational cross-sectional
study. All the participants were informed of its objectives
before the study and signed letter of consent in accordance
with the Helsinki Declaration Standards was obtained. Our
study cohort consisted of 110 patients, who underwent
coronary angiography for suspected coronary artery disease.
2.2. Inclusion criteria
Patients who underwent coronary angiogram for suspected
coronary artery disease and did not meet the exclusion
criteria.
2.3. Exclusion criteria
Patients who had chest deformities, chronic lung disease, poor
echo window, pericardial and/or pleural effusion on transtho-
racic echocardiography, previous coronary artery bypass graft
surgery (CABG), percutaneous coronary intervention (PTCA),
and chronic kidney disease were not included in the study. All
patients underwent detailed history, clinical examination,
anthropometric measurement, routine biochemistry, ECG, and
transthoracic echocardiography. Some of the patients had
already undergone exercise treadmill test.
2.4. Variables
Body mass index (BMI) was calculated as body weight in
kilograms and divided by height squared. Obesity was deﬁned
as having a BMI ≥30 kg/m2. Hypertension was deﬁned as
systolic blood pressure ≥140 mmHg, diastolic blood pressure
≥90 mmHg, or requirement for antihypertensive medication.10
Diabetes mellitus was deﬁned according to the criteria of theAmerican Diabetes Association or requirement for insulin or
oral hypoglycemic drugs.11 Hyperlipidemia was deﬁned as
total cholesterol higher than 220 mg/d or triglycerides
≥150 mg/dl.12
2.5. Echocardiographic measurement
Transthoracic echocardiography provides a reliable measure-
ment of EFT.
Transthoracic echocardiography for the purpose of mea-
suring epicardial fat thickness was done within 3 days after
coronary angiography. Echocardiograms were performed with
a PHILIPS HD 7 instrument according to standard techniques,
with subjects in the left lateral decubitus position. Echocar-
diographic images were recorded onto a computerized data-
base and videotape. The ofﬂine measurement of epicardial fat
thickness was performed by 2 cardiologists who were unaware
of the clinical and angiographic data. We measured epicardial
fat thickness on the free wall of right ventricle from the
parasternal long- and short-axis views, since it allows accurate
assessment.13,14 We preferred to measure at end-systole since
compression of epicardial fat layer occurs during diastole.6
Epicardial fat was identiﬁed as an echo-free space between the
myocardium and visceral pericardium. The epicardial fat
thickness was measured perpendicularly on the free wall of
the right ventricle at end-systole for 3 cardiac cycles. The
measurement was performed at a point on the free wall of the
right ventricle where the fat thickness was highest (Fig. 1). The
average value from 3 cardiac cycles for each echocardiographic
view was tabulated and used for the statistical analysis.
2.6. Coronary angiography
In a fasting state, coronary angiography was performed using
the Judkins' technique, by the femoral or radial artery
approach. The severity of coronary atherosclerotic lesions
was evaluated from at least 3 projections in all the patients by
modiﬁed Gensini scoring system. According to this scoring
system, coronary arterial system was divided into 8 segments
and the most severe luminal narrowing in each coronary
segment was graded with 1 to 4 points (between 1% and 49% – 1
point; 50% and 74% – 2 points; 75% and 99% – 3 points; 100% – 4
points). Each patient was evaluated with a total score between
0 and 32 points. Each point was multiplied with separate
coefﬁcients based on vessel and its segments; these coefﬁ-
cients were 5 for left major coronary artery, 2.5 for proximal
LAD, 1.5 for middle LAD, 1.5 for distal LAD, 1 for diagonal LAD,
2.5 for proximal circumﬂex artery, 1 for marginal obtuse and
posterolateral branch, 1.5 for right proximal coronary, 1 for
posterior descending artery, and 0.5 for others. The points
were added and total Gensini points were calculated for each
patient.5 Patients who had normal coronary angiograms and
negative treadmill test were used as controls.
2.7. Statistical analysis
Statistical analysis was done using SPSS 13.0 for windows.
Continuous variables are expressed as means  SD and
categorical variables as absolute numbers and percentages.
Comparisons of continuous variables were performed using
Fig. 1 – Epicardial fat thickness (EFT). Showing pericardial (thick head arrow) fat and epicardial fat (thin head arrow) in
parasternal long- and short-axis views.
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compared with the Chi-square test. Pearson correlation
analysis was used for analysis of correlation between EFT
and age, BMI, and serum lipids. The effect of EFT on the
presence and severity (Gensini scoring) of CAD was assessed
using analysis of covariance (ANCOVA) and Spearman's partial
correlation analysis, controlling for the confounding factors
including: diabetes, sex, age, smoking, dyslipidemia, and BMI.
Distribution of diabetes, hypertension, and smoking in normal
and CAD group was analyzed with Chi-square test. Statistical
signiﬁcance was set at <0.05.
3. Results
3.1. Demographic features
110 subjects in the range of 25–80 years were included. Mean
ages of normal and CAD groups were 51.5  10.6 and 52  9.6
years, respectively with no statistically signiﬁcant difference
( p = 0.559). Overall, 32 (64%) and 38 (63.3%) males were in
normal and CAD groups, respectively. Cardiovascular risk
factors were distributed in groups. Distribution of diabetes,
hypertension, smoking, dyslipidemia, and BMI in both control
and CAD groups were not signiﬁcantly different as per Chi-
square and unpaired t-test. Distribution of variables like
diabetes and dyslipidemia were similar in both sexes, unlike
other variables (Table 1).Table 1 – Distribution of variables according to sex.
Variables Male (n = 70) Female (n = 40)
Age 53.28  10.8 51.46  9.587
BMI 27.9300 (2.068) 27.4457 (1.903)
EFT 5.5575 (1.648) 5.9671 (2.304)
Hypertension 31 (44.3%) 22 (55.0%)
Dyslipidemia 21 (30.0%) 12 (30%)
Diabetus 22 (55.0%) 22 (55.0%)3.2. EFT and clinical variables
Epicardial fat thickness varied between 0.9 and 13.5 mm. Mean
of thickness in normal group was 4.4  1.2 mm and in CAD
group it was 6.9  1.9 mm (Fig. 2) that was statistically
signiﬁcant ( p = 0.0001). Additional ANCOVAs in both groups
(normal and CAD), with discussion of diabetes, sex, age,
smoking, dyslipidemia, and BMI, as dependent variables,
showed that the differences in EFT between both groups
had signiﬁcantly inﬂuenced the CAD presence ( p = 0.0001)
(Table 2). Correlation between EFT and age ( p = 0.870), and EFT
and BMI ( p = 0.08), was not statistically signiﬁcant. Although
Mean epicardial fat thickness was slightly higher in males, it
was not statistically signiﬁcant (Table 2).
3.3. Correlation between EFT and severity of CAD
Correlation EFT with severity of CAD with Spearman's analysis
(Spearman r = 0.3, p = 0.0001) is deﬁned, but despite confound-
ing variables again, EFT had positive correlation with the
severity of coronary diseases (Gensini scoring) by controlling
(partial correlation) confounding variables (Spearman
r = 0.704, p = 0.002) (Table 3). Mean of Gensini scoring in CADFig. 2 – Comparison of epicardial fat thickness (EFT) with
severity of coronary artery disease (Gensini score).
Table 2 – Comparison of variables in normal and coronary artery disease populations.
Variable Normal (n = 50) CAD (n = 50) p value
Age in years (mean  SD) 51.5  10.6 52.6  9.6 0.559
Male/female 32 (64%)/18 (36%) 38 (63%)/22 (36.6%) 0.942
Diabetes Mellitus 24 (48%) 26 (48%) 0.625
Hypertension 27 (54%) 26 (43%) 0.265
Smoking 11 (22%) 22 (36%) 0.095
Dyslipidemia 13 (26%) 20 (33%) 0.403
Eat 4.4  1.2 6.9  1.9 <0.0001
BMI 27.4  1.7 27.7  2.1 0.493
Table 3 – Spearman and Pearson correlation analysis of
EFT and variables.
Variables r p value
Age 0.016 0.870
BMI 0.164 0.087
Gensini score 0.704 0.000
Table 4 – ANCOVA result for both groups (normal and
CAD) with confounding factors.
Confounding variables bdf aF p value
Age 1 1.197 0.278
Sex 1 10.809 0.002
Smoking 1 0.009 0.923
Hypertension 1 0.026 0.873
Dyslipidemia 1 0.001 0.971
Diabetes mellitus 1 0.005 0.946
a F test assumes that the errors are normally distributed and
homoscedastic.
b df = degrees of freedom.
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of CAD is shown in Fig. 2.
4. Discussion
Our study reveals the association of EFT with severity of CAD.
Our study also showed correlation between cardiovascular risk
factors (smoking, diabetes, obesity, hyperlipidemia, age) and
EFT. Even though distribution of traditional risk factors such as
age, male sex, diabetes, smoking, and serum LDL had no
signiﬁcant difference in normal and CAD groups, the con-
founding effect of these risk factors was addressed by
controlling these factors, in ANCOVA test and the correlation
between EFT and presence of CAD was deﬁned ( p = 0.0001)
independently. EFT thickness emerged as an independent
predictor of CAD among other well-known risk factors.
Two potential mechanisms for this association have been
proposed: ﬁrst, EFT is a component of visceral adiposity and is
related to metabolic syndrome and cardiovascular risk
factors,15–17 secondly, EFT has paracrine and endocrine
functions. Iacobellis et al.18 have pointed out that epicardial
fat is clearly metabolically active and an important source of
both pro- (tumor necrosis factor-a, interleukin 1, interleukin 6,
nerve growth factor) and anti-(adiponectin) inﬂammatory
cytokine production, which might signiﬁcantly affect cardiac
function and morphology. It can secrete numerous bioactive
molecules (adipokines) such as adiponectin, resistin, and
inﬂammatory cytokines (interleukin-1b, interleukin-6, tumor
necrosis factor-a).4,7 Interestingly, inﬂammatory mediators
originating outside the coronary artery are also capable of
including compositional changes in the inner layer of
intima.17–19
There is a substantial amount of data demonstrating
associations between increased EFT thickness and volume as
assessed by echocardiography and coronary atherosclerosis. It
is of note that some of the studies indicate that an increased
amount of EFT is either not related to CAD or is merely a marker
of visceral and overall adiposity and that adding it to the already
existing cardiovascular risk assessment models does notenhance their predictive capabilities.20,21 More recent inves-
tigations have shown a signiﬁcant association between
epicardial fat and coronary artery disease by cardiac comput-
ed tomography scan.22,23 Iacobellis et al.8 have demonstrated
an excellent correlation between epicardial adipose tissue
and waist circumference, as well as the abdominal visceral
adipose tissue measured by magnetic resonance imaging.
These discrepancies may be to some extent the result of
varying methodologies and study populations. We also
showed that EFT independently was related to severity
( p = 0.042) of CAD. The correlation between EFT thickness
and the severity of CAD has been addressed previously.24,25
However, the results of these studies are conﬂicting, as they
did not assess patients with normal coronary arteries. Ahn
et al.26 showed that EFT was thicker in subjects with CAD than
in those without CAD, and that it might provide additional
information for assessing CAD risk and predicting the extent
and activity of CAD.27,28
In this study, we deﬁned that increased EFT correlated with
severity of the coronary artery stenosis without confounding
effect of dependent variables. In our study, EFT on the right
ventricle varied between 0.9 and 13.5 mm. Epicardial fat
thickness was almost similar in males and females (Table 4)
that may be because of similar BMI in women and men.29,30
Inﬂammation has been identiﬁed as a potential target for
therapeutic intervention in patients with CAD.21 Inﬂammatory
mediators derived EFT was a favorable target for preventive
intervention and novel therapeutic strategies, and these
interventions (such as aspirin, angiotensin-converting en-
zyme inhibitor, statin, and specially exercise and weight loss)
may also have anti-inﬂammatory effect and decreasing
epicardial fat volume, but more studies are required for
approving this hypothesis.31
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We could not conﬁrm epicardial fat thickness using the
standard MRI and CT methods. Echocardiography was a
relatively simple and inexpensive method, but the accuracy
and reproducibility should be further tested. In addition, as
epicardial adipose tissue has a 3-dimensional distribution, 2-
dimensional echocardiography may not completely assess the
total amount of epicardial adiposity. Further evaluation may
be necessary.
5. Conclusion
In this study, epicardial fat thickness (assessed by a simple
bedside tool like transthoracic echocardiography) was higher
in CAD group than in normal patients. EFT measured using
this technique signiﬁcantly correlated with the severity of
coronary artery stenosis and can be used for risk stratiﬁcation.
Being a noninvasive technique, it can be repeated as many
times as possible, and hence has the potential to monitor the
response to life-style modiﬁcation and therapy. However, a
larger study involving more number of patients with longer
period of follow-up is mandatory.
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